Keeping you up to date with the latest clinical trial information
Chronic Obstructive Pulmonary Disease
Characterization of T Lymphocytes in Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is a global epidemic of major proportions that is predicted to become the third most common cause of death and fifth most frequent cause of chronic disability by 2020.
Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? – study protocol for a randomized controlled trial
Systemic inflammation is associated with various complications in chronic obstructive pulmonary disease including weight loss, cachexia, osteoporosis, cancer and cardiovascular diseases.
Work life of persons with asthma, rhinitis, and COPD: A study using a national, population-based sample
To estimate the duration of work life among persons reporting a physician's diagnosis of COPD, asthma, or rhinitis compared to those with select non-respiratory conditions or none and to delineate the factors associated with continuance of employment.
A Long-Term Safety Study of Infliximab in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this long-term observational study is designed to collect additional information on incidence of cancer and cause of death among patients who have participated in clinical trials of infliximab in the treatment of COPD.
Effects of Bronchodilators in Mild COPD
The purpose of this long-term observational study is designed to collect additional information on incidence of cancer and cause of death among patients who have participated in clinical trials of infliximab in the treatment of COPD.
Advair HFA is a new non-chlorofluorocarbon inhalation aerosol formulation of fluticasone and salmeterol indicated for the long-term, twice-daily maintenance treatment of asthma in patients 12 years of age and older.
